This activity is provided by prIME Oncology.
CONTINUING MEDICAL EDUCATION
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.
This activity is supported by educational grants from Bristol-Myers Squibb, EMD Serono, and Pfizer.
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity.
Dr Gilligan has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Haanen has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Jacobson has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
- Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
DISCLOSURE REGARDING UNLABELED USE
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.